Corvus Pharmaceuticals, a biopharmaceutical company specializing in clinical stage immuno-oncology therapies, has announced its focus on the development and commercialization of Mupadolimab (CPI-006), an anti-CD73 monoclonal antibody specifically targeting non-small cell lung cancer and head and neck cancers. Currently in Phase Ib/II clinical trials, the company's lead candidate hopes to offer patients a more effective treatment option. Additionally, Corvus Pharmaceuticals is developing CPI-818, a covalent inhibitor of ITK, and Ciforadenant (CPI-444), an oral, small molecule antagonist of the A2A receptor, with the former in Phase I/Ib clinical trial to treat malignant T-cell lymphomas and the latter in Phase II clinical trial for advanced or refractory renal cell cancer. The company's preclinical stage products include CPI-182, an antibody aimed at blocking inflammation and suppressing Myeloid, as well as CPI-935, an adenosine A2B receptor antagonist intended to prevent fibrosis. Corvus Pharmaceuticals' strategic collaboration with Angel Pharmaceuticals further underscores its commitment to bringing targeted investigational medicines to market. The Burlingame, California-based company was incorporated in 2014.
Corvus Pharmaceuticals's ticker is CRVS
The company's shares trade on the NASDAQ stock exchange
They are based in Burlingame, California
There are 51-200 employees working at Corvus Pharmaceuticals
It is corvuspharma.com
Corvus Pharmaceuticals is in the Healthcare sector
Corvus Pharmaceuticals is in the Biotechnology industry
The following five companies are Corvus Pharmaceuticals's industry peers: